BioNTech (NASDAQ:BNTX) Given "Outperform" Rating at BMO Capital Markets

BioNTech (NASDAQ:BNTX - Get Free Report)'s stock had its "outperform" rating reissued by equities research analysts at BMO Capital Markets in a research report issued to clients and investors on Monday, Marketbeat reports.

A number of other analysts have also issued reports on BNTX. Evercore ISI raised BioNTech from an "in-line" rating to an "outperform" rating and raised their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Berenberg Bank began coverage on shares of BioNTech in a research report on Tuesday, November 19th. They issued a "buy" rating and a $130.00 target price on the stock. Jefferies Financial Group raised shares of BioNTech from a "hold" rating to a "buy" rating and upped their price target for the stock from $96.00 to $150.00 in a research report on Tuesday, September 17th. HSBC increased their price target on shares of BioNTech from $97.00 to $136.00 and gave the stock a "buy" rating in a research note on Monday, October 7th. Finally, Morgan Stanley raised shares of BioNTech from an "equal weight" rating to an "overweight" rating and boosted their price objective for the company from $93.00 to $145.00 in a research note on Tuesday, September 24th. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $138.67.

BioNTech Price Performance

BioNTech stock traded down $1.19 during midday trading on Monday, reaching $117.20. 599,012 shares of the company were exchanged, compared to its average volume of 814,941. The firm's 50-day simple moving average is $113.81 and its 200-day simple moving average is $98.77. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The company has a market capitalization of $28.10 billion, a price-to-earnings ratio of -56.68 and a beta of 0.26. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33.

BioNTech (NASDAQ:BNTX - Get Free Report) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion during the quarter, compared to the consensus estimate of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's quarterly revenue was up 38.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.73 earnings per share. On average, analysts anticipate that BioNTech will post -3.72 EPS for the current year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently bought and sold shares of BNTX. GAMMA Investing LLC increased its position in shares of BioNTech by 21.7% during the third quarter. GAMMA Investing LLC now owns 623 shares of the company's stock worth $74,000 after acquiring an additional 111 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in shares of BioNTech by 106.3% in the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company's stock valued at $43,000 after purchasing an additional 252 shares in the last quarter. Blue Trust Inc. boosted its stake in shares of BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company's stock valued at $55,000 after buying an additional 388 shares during the last quarter. Gallacher Capital Management LLC grew its position in shares of BioNTech by 12.1% during the second quarter. Gallacher Capital Management LLC now owns 3,657 shares of the company's stock worth $294,000 after buying an additional 395 shares in the last quarter. Finally, TD Asset Management Inc increased its stake in shares of BioNTech by 6.1% in the second quarter. TD Asset Management Inc now owns 7,590 shares of the company's stock worth $612,000 after buying an additional 435 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.